INDV Stock Forecast & Price Target

Indivior Pharmaceuticals Inc. has demonstrated significant growth in its Sublocade treatment, with the number of patients rising to approximately 171,500 in the third quarter of 2025, marking an 8% increase from the previous year. The company has also expanded its prescriber base to around 8,568, reflecting an 11% year-over-year growth, which is expected to support higher sales projections. Management's updated guidance for worldwide Sublocade sales of $825 million to $845 million indicates a robust annual growth outlook, bolstered by ongoing expansion in the long-acting injectable opioid use disorder market and effective cost control measures that could enhance long-term EBITDA growth.

Indivior Pharmaceuticals is experiencing a significant reduction in its market footprint for Sublocade, with commercial support dropping from approximately 40 countries to just four, indicating challenges in maintaining a broad customer base. Furthermore, the decision to discontinue support for Opvee suggests a strategic retreat that may harm overall revenue diversification within the company's portfolio. Consensus projections point to a revenue decline of about 6.5% in 2026, reflecting wider concerns about the sustainability of growth driven primarily by Sublocade, along with potential impacts on EBITDA margins despite improved guidance.